Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/23/2025 | $17.00 → $33.00 | Buy | H.C. Wainwright |
| 1/10/2025 | $21.00 | Buy | B. Riley Securities |
| 1/6/2025 | $15.00 → $17.00 | Buy | H.C. Wainwright |
| 9/4/2024 | $9.00 | Buy | H.C. Wainwright |
| 5/6/2024 | $8.00 | Buy | Craig Hallum |
| 10/14/2021 | $10.00 | Buy | B. Riley Securities |
DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will hold a virtual Investor Day and report fourth quarter 2024 financial results on Tuesday, March 18, 2025, beginning at 10:00 a.m. ET (9:00 a.m. CT). In addition to discussing fourth quarter 2024 financial results, the Investor Day event will offer investors an in-depth look at Eton's rare disease portfolio and financial outlook after a transformational six months. The company will share its view of the long-term market opportunity and c
– Eton expects to significantly expand patient access to this critical treatment for Wilson disease patients –– $0 co-pay for all eligible patients and best-in-class patient support services –– Now available exclusively through Optime Care – DEER PARK, Ill., March 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has launched Galzin® (zinc acetate) capsules. Galzin is FDA-approved for the maintenance treatment of patients with Wilson disease who have been initially treated with a chelating agent. It is the only F
- Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration's (FDA) Orange Book upon the product's approval – DEER PARK, Ill., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent No. 12,214,010, covering its ET-600 product candidate's proprietary formulation of desmopressin oral solution. The patent expires in 2044 and is expected to be listed in the FDA Orange Book upon th
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $33.00 from $17.00 previously
B. Riley Securities initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $21.00
H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $17.00 from $15.00 previously
SC 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13D/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
SCHEDULE 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). Ms. Erdogan-Trinkaus brings to the Company broad commercial experience in the pharmaceutical
DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through the end of May to ensure a smooth transition. "We are pleased to welcome James to the Eton team. He brings a wealth of experience managing the finance and accounting activities for some of the most successful companies in the industry. We look forward to benefiting from his financial expertise as we
LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the "Board"). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier has also been appointed as a member of the Audit Committee and Corporate Governance and Nominating Committee and Chair of the Compensation Committee. Mr. Maier joins Small Pharma with over 30 years' ex
Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024 product sales increased 40% over Q3 2023, representing 15th straight quarter of sequential product sales growthProduced positive quarterly GAAP net income from product sales for first time in company historyGenerated cash from operations of $2.9 million in Q3 2024Granted additional patent for ET-400Management to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical c
DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial in (Audio Only) Toll-free: 888-596-4144 Non-toll free: 646-968-2525 Access Code: 1144771 Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions fr
Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results